Home  »  Trendy Stocks   »  Ocugen Inc. (OCGN) stock gains in the pre-market t...

Ocugen Inc. (OCGN) stock gains in the pre-market trading session. What’s driving it higher?

Ocugen Inc. (NASDAQ: OCGN) stock declined by 2.13% at the last trading close whereas the OCGN stock price rises by 16.30% in the pre-market trading. Ocugen, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of gene therapy to treat blindness and the development of a COVID-19 vaccine.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


What is happening?

On April 20, 2021, it was being announced that Bharat Biotech initially developed a coronavirus vaccine, which Ocugen would soon co-develop and produce. Given the enormous need for such vaccinations around the world, the deal’s near-term sales prospects may be enormous. It’s true that there’s plenty of demand for more coronavirus vaccines on the market, but the facts matter.

Bharat Biotech, a co-development partner, on 21, April 2021 reported promising findings from the second interim review of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate, in its Phase 3 trial, but it has yet to be approved by the US Food and Drug Administration. That’s a challenge because Ocugen’s commercialization agreement only applies to the United States, where vaccination is moving ahead of time with vaccines that have already been approved for sale.

As a result, the sales capacity is expected to be lower than Reddit traders had anticipated.COVAXIN had a 78 percent efficacy against mild, moderate, and serious COVID-19 disease, with a 100 percent efficacy against severe COVID-19 disease alone.

Also,

The reality is that the OCGN can only receive 45 percent of the revenues from Covaxin purchases in the United States. Ocugen is a biotech company in the early stages with no clinical trials underway; it is not a pharmaceutical company. In other words, it has no track record of profitably producing something, let alone a commodity created by anyone else. It doesn’t mean it’ll crash, but it does mean that investors should be aware that it’s a much riskier bet than it seems on the surface.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Biotech Stocks to Buy for Sep-2021

Biotechnology (biotech) refers to the use of microbes and cellular biology in health-related research and development. It is not just therapies that biotechnology companies develop.

635

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam